2017AAAAI_ACAAI临床指南：药物治疗季节性过敏性鼻炎.pdfVIP

CLINICAL GUIDELINE Annals of Internal Medicine Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters Dana V. Wallace, MD; Mark S. Dykewicz, MD; John Oppenheimer, MD; Jay M. Portnoy, MD; and David M. Lang, MD Description: The Joint Task Force on Practice Parameters, Recommendation 1: For initial treatment of seasonal allergic which comprises representatives of the American Academy of rhinitis in persons aged 12 years or older, routinely prescribe Allergy, Asthma and Immunology (AAAAI) and the American monotherapy with an intranasal corticosteroid rather than an in- College of Allergy, Asthma and Immunology (ACAAI), tranasal corticosteroid in combination with an oral antihistamine. formed a workgroup to review evidence and provide guidance (Strong recommendation) to health care providers on the initial pharmacologic treatment of seasonal allergic rhinitis in patients aged 12 years or Recommendation 2: For initial treatment of seasonal allergic older. rhinitis in persons aged 15 years or older, recommend an intranasal corticosteroid over a leukotriene receptor antagonist. Methods: To update a prior systematic review, the workgroup (Strong recommendation) searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 18 July 2012 to 29 July 2016 to Recommendation 3: For treatment of moderate to severe sea- identify studies that addressed efficacy and adverse effects of sonal allergic rhinitis in persons aged 12 years or older, the clini- single or combination ph